Oncology company OSI Pharmaceuticals Inc. is fronting $55 million to Serono SA for U.S. marketing rights to the cancer indications of a long-approved but oft-shuffled drug. (BioWorld Today)

Oncology company OSI Pharmaceuticals Inc. is fronting $55 million to Serono SA for U.S. marketing rights to the cancer indications of a long-approved but oft-shuffled drug. (BioWorld Today)